---
title: "海创药业股份有限公司 (688302.SH)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/688302.SH.md"
symbol: "688302.SH"
name: "海创药业股份有限公司"
industry: "制药"
---

# 海创药业股份有限公司 (688302.SH)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 沪深市场 |
| Website | [www.hinovapharma.com](https://www.hinovapharma.com) |

## Company Profile

公司是一家专注于癌症和代谢性疾病的全球化创新药物企业，以 “创良药·济天下” 为使命，以为患者提供有效、安全、可负担的药物为重点，致力于研发和生产满足重大临床需求、具有全球权益的创新药物。公司是一家创新驱动型的国际化创新药企业。公司以靶向蛋白降解 PROTAC 技术和氘代技术等平台为基础，专注于癌症、代谢性疾病等具有重大市场潜力的治疗领域的创新药物研发。主要产品:HC-1119、HP518、HP568、HP501、HP515、HP537 及 HP560。企业荣誉:2019 中国化药研发实力排行榜 TOP100、2020 中国健康新势力·化学制剂行业新势力企业、成都市新经济百家重点培育企业等。2...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-16T04:30:09.000Z

**Overall: C (0.46)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 153 / 222 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 21414.67% |  |
| Net Profit YoY | 31.22% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 4.06 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4.46B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 23.58M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -12.40% | D |
| Profit Margin | -612.36% | E |
| Gross Margin | 99.62% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 21414.67% | A |
| Net Profit YoY | 31.22% | B |
| Total Assets YoY | -2.96% | D |
| Net Assets YoY | -10.61% | D |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -16.33% | D |
| OCF YoY | 21414.67% | A |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.02 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 19.24% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 海创药业股份有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-12.40%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-612.36%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "99.62%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "21414.67%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "31.22%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.96%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-10.61%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-16.33%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "21414.67%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.02",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "19.24%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 艾力斯 (SH.688578) | A | A | B | A | B | A |
| 02 | 兴齐眼药 (SZ.300573) | A | A | A | B | B | A |
| 03 | 恒瑞医药 (SH.600276) | A | B | C | A | B | B |
| 04 | 云南白药 (SZ.000538) | B | C | B | B | C | B |
| 05 | 信立泰 (SZ.002294) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -30.89 | 194/222 | - | - | - |
| PB | 4.06 | 169/222 | 4.75 | 4.33 | 3.33 |
| PS (TTM) | 189.15 | 221/222 | 15585.05 | 487.03 | 212.43 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-12-09T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 50% |
| Overweight | 1 | 50% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 45.10 |
| Highest Target | 80.00 |
| Lowest Target | 80.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/688302.SH/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/688302.SH/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/688302.SH/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
